Condition
Macular Degeneration Choroidal Neovascularization
Total Trials
4
Recruiting
1
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 4 (2)
Trial Status
Completed2
Unknown1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06742307Phase 4RecruitingPrimary
Faricimab Quarterly Maintenance for Neovascular Age Related Macular Degeneration
NCT07090044Phase 4Completed
Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour Period
NCT05969418CompletedPrimary
Deep Learning Optical Coherence Tomography (OCT) and OCT Angiography (OCTA) in NVC
NCT02988895Not ApplicableUnknownPrimary
Episcleral Brachytherapy for the Treatment of Wet AMD
Showing all 4 trials